Establishment of specific cytotoxic T lymphocyte culture system and its inhibitory effect on ovarian cancer

Sui,Mingxing; Si,Lihui; Xu,Tianmin; Cui,Manhua

doi:10.3892/ol.2016.5202

Establishment of specific cytotoxic T lymphocyte culture system and its inhibitory effect on ovarian cancer

Authors:
- Mingxing Sui
- Lihui Si
- Tianmin Xu
- Manhua Cui
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China
Published online on: September 28, 2016 https://doi.org/10.3892/ol.2016.5202
Pages: 4087-4093

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to establish a novel method for efficiently inducing cytotoxic T lymphocytes (CTLs) in vitro, in order to develop an immune‑based therapy for suppressing and killing ovarian cancer cells with a high safety and efficacy. Peripheral blood mononuclear cells (PBMCs) were stimulated with CpG oligodeoxynucleotide (CpGODN) and ginsenoside Rg1, which were united as an immune adjuvant, and human epidermal growth factor receptor 2 (HER2/neu) antigen peptide, in order to establish a specific CTL culture system in vitro. Chromosome karyotype analysis, growth curve construction and flow cytometric analysis of immune phenotypes, including cluster of differentiation (CD)3, CD4 and CD8, were performed to characterize the stimulated PBMCs in vitro. Subsequently, SKOV3 ovarian cancer cells were treated with the specific CTL culture system in vitro, and MTT assays were performed to test the inhibitory and lethal effects of the CTLs on SKOV3 cells. The number of CTLs was significantly increased from day 7 of stimulation with the specific mixture (CpGODN, ginsenoside Rg1 and HER2/neu) (P<0.01), and plateaued on day 19. Following activation, the number of CD3+, CD3+CD4+ and CD3+CD8+ cells was significantly increased (P<0.01). The lymphocyte karyotype did not change following exposure to antigen. After treatment with the specific CTL system, the number of SKOV3 cells in the experimental group was significantly reduced compared with that in the control group (P<0.01). The results of the present study suggested that two novel immune adjuvants, CpGODN and ginsenoside Rg1, could be combined with the HER2/neu antigen peptide to establish a specific CTL culture system in vitro. This system demonstrated a high antigen specificity, safety and proliferative ability, and exerted significant lethal and inhibitory effects on SKOV3 cells in vitro.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol. 18(Suppl 2): S19–S32. 2005. View Article : Google Scholar : PubMed/NCBI
3	Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, et al: A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 119:3454–3461. 2013. View Article : Google Scholar : PubMed/NCBI
4	Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M, Huang P and Yu D: Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin J Cancer Res. 26:564–572. 2014.PubMed/NCBI
5	Lenhard SM, Bufe A, Kümper C, Stieber P, Mayr D, Hertlein L, Kirschenhofer A, Friese K and Burges A: Relapse and survival in early-stage ovarian cancer. Arch Gynecol Obstet. 280:71–77. 2009. View Article : Google Scholar : PubMed/NCBI
6	Mantia-Smaldone GM, Corr B and Chu CS: Immunotherapy in ovarian cancer. Hum Vaccin Immunother. 8:1179–1191. 2012. View Article : Google Scholar : PubMed/NCBI
7	Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA and Coukos G: Intraepithelial T cells and tumor proliferation: Impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer. 115:2891–2902. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N Engl J Med. 348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
9	Rosenberg SA, Restifo NP, Yang JC, Morgan RA and Dudley ME: Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008. View Article : Google Scholar : PubMed/NCBI
10	Berek J, Taylor P, McGuire W, Smith LM, Schultes B and Nicodemus CF: Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 27:418–425. 2009. View Article : Google Scholar : PubMed/NCBI
11	Dadmarz RD, Ordoubadi A, Mixon A, Thompson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA and Schwartzentruber DJ: Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am. 2:263–272. 1996.PubMed/NCBI
12	Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ and Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol. 96:422–430. 2000. View Article : Google Scholar : PubMed/NCBI
13	Smith KA: Interleukin-2: Inception, impact, and implications. Science. 240:1169–1176. 1988. View Article : Google Scholar : PubMed/NCBI
14	Gri G, Gallo E, Di Carlo E, Musiani P and Colombo MP: OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J Immunol. 170:99–106. 2003. View Article : Google Scholar : PubMed/NCBI
15	Coumes F, Huang CY, Huang CH, Coudane J, Domurado D, Li S, Darcos V and Huang MH: Design and development of immunomodulatory antigen delivery systems based on peptide/PEG-PLA conjugate for tuning immunity. Biomacromolecules. 16:3666–3673. 2015. View Article : Google Scholar : PubMed/NCBI
16	Preston CC, Goode EL, Hartmann LC, Kalli KR and Knutson KL: Immunity and immune suppression in human ovarian cancer. Immunotherapy. 3:539–556. 2011. View Article : Google Scholar : PubMed/NCBI
17	Meden H and Kuhn W: Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: A new prognostic factor. Eur J Obstet Gynecol Reprod Biol. 71:173–179. 1997. View Article : Google Scholar : PubMed/NCBI
18	Wang SC and Hung MC: HER2 overexpression and cancer targeting. Semin Oncol. 28:115–24. 2001. View Article : Google Scholar : PubMed/NCBI
19	Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E and Camilleri-Broët S: HER2 status in ovarian carcinomas: A multicenter GINECO study of 320 patients. PLoS One. 2:e11382007. View Article : Google Scholar : PubMed/NCBI
20	Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B and Høgdall CK: Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: From the Danish MALOVA ovarian cancer study. Cancer. 98:66–73. 2003. View Article : Google Scholar : PubMed/NCBI
21	Teplinsky E and Muggia F: Targeting HER2 in ovarian and uterine cancers: Challenges and future directions. Gynecol Oncol. 135:364–370. 2014. View Article : Google Scholar : PubMed/NCBI
22	Klinman DM, Klaschik S, Sato T and Tross D: CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev. 61:248–255. 2009. View Article : Google Scholar : PubMed/NCBI
23	Xia Y, Gupta GK, Castano AP, Mroz P, Avci P and Hamblin MR: CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer. J Biophotonics. 7:897–905. 2014. View Article : Google Scholar : PubMed/NCBI
24	Qi LW, Wang CZ and Yuan CS: American ginseng: Potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol. 80:947–954. 2010. View Article : Google Scholar : PubMed/NCBI
25	Lee EJ, Ko E, Lee J, Rho S, Ko S, Shin MK, Min BI, Hong MC, Kim SY and Bae H: Ginsenoside Rg1 enhances CD4(+) T-cell activities and modulates Th1/Th2 differentiation. Int Immunopharmacol. 4:235–244. 2004. View Article : Google Scholar : PubMed/NCBI
26	Su F, Yuan L, Zhang L and Hu S: Ginsenosides Rg1 and Re act as adjuvant via TLR4 signaling pathway. Vaccine. 30:4106–4112. 2012. View Article : Google Scholar : PubMed/NCBI
27	Posevitz-Fejfár A, Posevitz V, Gross CC, Bhatia U, Kurth F, Schütte V, Bar-Or A, Meuth SG and Wiendl H: Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: Implications for immune cell biobanking. PLoS One. 9:e1159202014. View Article : Google Scholar : PubMed/NCBI
28	Weidanz JA, Nguyen T, Woodburn T, Neethling FA, Chiriva-Internati M, Hildebrand WH and Lustgarten J: Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol. 177:5088–5097. 2006. View Article : Google Scholar : PubMed/NCBI
29	Conrad H, Gebhard K, Krönig H, Neudorfer J, Busch DH, Peschel C and Bernhard H: CTLs directed against HER2 specifically cross-react with HER3 and HER4. J Immunol. 180:8135–8145. 2008. View Article : Google Scholar : PubMed/NCBI
30	Mittendorf EA, Holmes JP, Ponniah S and Peoples GE: The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother. 57:1511–1521. 2008. View Article : Google Scholar : PubMed/NCBI
31	Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B and Kiessling R: HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother. 58:653–664. 2009. View Article : Google Scholar : PubMed/NCBI
32	Shaffer LG and Tommerup N: An international system for human cytogenetic nomenclature (2005). S Karger AG; Basel: 2005
33	Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS and Lee PP: Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 1:e282004. View Article : Google Scholar : PubMed/NCBI
34	Yee C, Gilbert MJ, Riddell SR, Brichard VG, Fefer A, Thompson JA, Boon T and Greenberg PD: Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol. 157:4079–4086. 1996.PubMed/NCBI
35	Zsiros E, Tanyi J, Balint K and Kandalaft LE: Immunotherapy for ovarian cancer: Recent advances and perspectives. Curr Opin Oncol. 26:492–500. 2014. View Article : Google Scholar : PubMed/NCBI
36	Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief CJ and Nijman HW: Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev. 9:CD0072872014.PubMed/NCBI
37	Powell BS, Andrianov AK and Fusco PC: Polyionic vaccine adjuvants: Another look at aluminum salts and polyelectrolytes. Clin Exp Vaccine Res. 4:23–45. 2015. View Article : Google Scholar : PubMed/NCBI
38	Sachamitr P, Hackett S and Fairchild PJ: Induced pluripotent stem cells: Challenges and opportunities for cancer immunotherapy. Front Immunol. 5:1762014. View Article : Google Scholar : PubMed/NCBI
39	Montoro E, Lemus D, Echemendia M, Martin A, Portaels F and Palomino JC: Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinicalisolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 55:500–505. 2005. View Article : Google Scholar : PubMed/NCBI